Intellect Neurosciences, Inc. (ILNS) Trader Alert

By | Pharmaceutical | No Comments

Neurological disease biotech company Intellect Neurosciences, Inc. (ILNS) is starting to get the attention of traders as news continues circulating online.

ILNS develops therapy agents to treat and prevent degenerative diseases of the brain. Currently they have several products under license including OX1 and Antisenilin® which are in phase I/II studies. In addition, Intellect Neurosciences has two preclinical products, TauC3, for the treatment of Alzheimers and CONJUMAB-A, for the treatment of amyloidosis.

ILNS has a research collaboration agreement with Medical Research Council Technology and license agreements with South Alabama Medical Science Foundation, New York University, AHP Manufacturing BV, and Northwestern University.

Intellect Neurosciences, Inc. (ILNS) common stock was recently approved for trading on the OTCQB. ILNS stock is currently trading at $0.28 a share with 3.3 million shares outstanding. The 52-week high was $5.00 on Feb. 15 2015 and the low $0.18 on May 27, 2015.

3 Biotech Small Cap Stocks to Watch: CASI, CRIS and EXEL

By | Pharmaceutical | No Comments

CASI Pharmaceuticals Inc. (CASI) is a clinical stage company with cancer treatment drugs in phase I and phase II. CASI has a market cap of $59 million with a stock price at $1.84 a share. Shares have reached a 52-week high of $2.13 on June 17, 2015 and a low of $1.07 in December 2014.

Currently company insiders own 37% of CASI Pharmaceuticals company shares with institutional investors holding 14%. CASI stock has a 50-Day MA of $1.52 and a 200-Day MA of $1.51. CASI reported $9.46 million in total cash and $1.41 in debt as of March 31, 2015 with a cash burn rate of about $4 million annually.

Curis, Inc. (CRIS) has 6 cancer treatment products in its product pipeline, one which is currently being marketed. Curis, Inc. stock is currently trading at $3.12 per share with a market cap of about $400 million. The stock has done well in the last 12 months gaining over 200% from $1.10 a share to a high of $3.65 a share on June 2, 2015. Many Wall Street analysts are bullish on CRIS with projections of $5 to $7 per share. The next earnings report is scheduled in early August.

Another small cap stock to watch in the pharmaceutical biotech arena is Exelixis, Inc. (EXEL). EXEL develops cancer treatment drugs and are involved in two Phase III trials. Exelixis, Inc. has a market cap of $723 million with a current stock price of $3.58 per share. EXEL stock has a 52-week high of $4.55 a share on July 28, 2014 and a low of $1.26 per share in late December 2014.

Galena Biopharma, Inc. (GALE) Stock Watch

By | Pharmaceutical | No Comments

When Galena Biopharma, Inc. (NASDAQ: GALE) stock gained nearly 60% in 2 weeks it certainly raised some eyebrows. So here at TKO we took a closer look at this small cap company for some answers.

A quick look at GALE financials certainly isn’t a reason to jump on the Galena Biopharma train if you’re looking for operational profits. With a quarterly cash burn of around $10 million and $52 million in cash, another round of financing is around the corner probably in middle to late 2016.

However, a peek at the GALE product pipeline is promising. Galena Biopharma focuses on developing and commercializing oncology therapeutics which are largely unmet in the cancer care market. This Investopedia article covers their products including Abstral, Zuplenz and their flagship breast cancer product NeuVax. The article also points to a glowing analyst report from Maxim Group as the reason for the recent GALE stock mini-meteoric rise. We surmise that the Maxim Group target price of $7.00 per share attracted the attention of day traders pushing volume well above averages.

Galena Biopharma, Inc. (GALE) is certainly a small cap pharma stock to watch. The success of Neuvax would make $1.50 a share a very shrewd investment, but commercialization is certainly years down the road giving investors plenty of opportunities to jump on board. GALE is currently selling at $1.87 per share above a 52-week low of $1.27 (May 8, 2015) and high hitting $3.36 a share back in July, 2014.

Cogentix Medical Inc (CGNT) Small Cap Stock Alert

By | Pharmaceutical | No Comments

With the Uroplasty Inc. and Vision-Sciences, Inc. merger in the rear view mirror, Cogentix Medical Inc (NASDAQ: CGNT) CEO Rob Kill’s vision of a $100 million company is half way there. The combined revenue from the merger is roughly $50 million, doubling Uroplasty Inc.’s 2014 income.

Cogentix Medical is a global medical device company that designs and manufactures products for the urology, gynecology, ear, nose and throat (ENT) and the gastrointestinal (GI) markets. Product information can be found at the CGNT website.

The completed merger has caught the attention of some analysts who have initiated coverage with a combined mean target of $2.95 a share.

CGNT stock is currently trading at about $1.70 per share just above a 52-week low of $1.42 in late April 2015 and well below a high of $6.20 per share (July 2014) before the merger completion. The next earnings report is due out in early August 2015.

Stay tuned TKO’ers!

NovaBay Pharmaceuticals, Inc. (NBY) Stock Alert

By | Pharmaceutical | No Comments

With commercial sales of Avenova™ accelerating, the stock of NovaBay Pharmaceuticals, Inc. (NYSE: NBY) is certainly on the TKO radar.

NovaBay Pharmaceuticals, Inc. (“NovaBay” or NBY) is a commercial stage company which launched its eye care product, Avenova with Neutrox™, in August 2014. The product is targeting a substantial evergreen market of 30 million Americans suffering from the chronic eyelid inflammation disease known as Blepharitis. Symptoms include dry and itchy eyes, contact lens discomfort, and eye discharge. Blepharitis is a form of staph bacteria that can lead to complications including conjunctivitis, dry eye syndrome and cornea damage. Avenova with Neutrox™ is a proven effective daily cleanse treatment for Blepharitis when used daily.

NovaBay also started the commercial launch of its wound care product NeutroPhase® in China. NBY reported their Chinese partner placed an order for 200,000 units which are undergoing fulfillment. The commercial launch for NeutroPhase® also includes partners in the USA, Ukraine, Egypt, Saudi Arabia, South Korea and more. These distribution channels could be useful for NBY in the future as the company has many more products in their pipeline using their anti-infection solutions.

If all goes according to company projections, NBY stock should do nicely as sales continue to grow through 2015. NovaBay Pharmaceuticals, Inc. (NBY) stock is currently trading around $0.75 a share with a 52-week low of $0.42 and the high hitting $1.30 in August 2014.

Stay tuned TKO’ers!